Back to Freepaper Session
Clinical investigation into the safety and efficacy of a presbyopic excimer treatment in post-LASIK Eyes: 6 months follow-up
Session Title: Presbyopia Correction
Session Date/Time: Monday 07/10/2013 | 16:30-18:15
Paper Time: 16:42
Venue: Emerald (First Floor)
First Author: : R.Ang PHILIPPINES
Co Author(s): :
To determine the safety and efficacy of an excimer LASIK treatment for presbyopia in patients who have previously undergone LASIK surgery
Department of Cornea and Refractive Surgery, Asian Eye Institute, Philippines
In this single centre, single surgeon, prospective study, a monolateral Supracor LASIK treatment (Bausch + Lomb Technolas) was performed in 30 post-LASIK presbyopic patients with the Technolas 217P excimer laser. Measured outcomes include visual acuity, safety, refraction and a subjective patient questionnaire over a 6 month follow-up period. Target refraction was -0.5D.
The mean patient age was 50.8 years. Preoperative mean spherical equivalent (SE) was 0.11D and mean cylinder was 0.5D. At 6 months post-operative (16 eyes), mean SE was -0.32D and mean cylinder was 0.55D. Monocular uncorrected near visual acuity (UNVA) improved from 22% at 0.8 pre-operatively to 69% at 1.0 or better 6 months post-operatively. 81% patients have binocular UNVA of 1.0 or better post-operatively. Uncorrected intermediate visual acuity (UIVA) improved from 31.6% at 1.0 or better pre-operatively to 85.7% at 1.0 better at 6 months post-op. Monocular uncorrected distance visual acuity (UDVA) remained stable post-operatively, with a slight improvement in post-operative binocular UDVA recorded compared with pre-operative. Good patient satisfaction was reported and 94% of patients would recommend the procedure to their friends.
The initial six month results find the Supracor Lasik procedure is a safe and effective treatment option for post-lasik patients with presbyopia. The procedure improves near and intermediate vision, with minimal impact on distance vision.
... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented